Biosimilars

Five things for pharma marketers to know: Wednesday, November 22, 2017

Five things for pharma marketers to know: Wednesday, November 22, 2017

WebMD reportedly lays off 10% of workforce; Roche blocks Herceptin biosimilar with patent suit; insurers cover Collegium's Xtampza over Purdue's OxyContin

Five things for pharma marketers to know: Wednesday, November 15, 2017

Five things for pharma marketers to know: Wednesday, November 15, 2017

By

FDA approves AstraZeneca asthma drug; Senate tax reform bill would repeal Obamacare mandate; J&J drops Remicade biosimilar lawsuit

Why haven't biosimilars gained ground in the U.S.?

Why haven't biosimilars gained ground in the U.S.?

By

Two years after the first biosimilar approval in the U.S., biosimilars have yet to match sales forecasts. What is their path forward?

Five things for pharma marketers to know: Wednesday, October 25, 2017

Five things for pharma marketers to know: Wednesday, October 25, 2017

By

FDA develops resources about biosimilars for HCPs; Biogen negotiates royalties for experimental Alzheimer's drug; GSK Q3 sales driven by HIV, respiratory drugs

Five things for pharma marketers to know: Monday, October 23, 2017

Five things for pharma marketers to know: Monday, October 23, 2017

By

Biosimilars could save $54 billion in next decade; White House requests drug-pricing task force; FDA approves GSK shingle vaccine

Five things for pharma marketers to know: Wednesday, September 20, 2017

Five things for pharma marketers to know: Wednesday, September 20, 2017

By

Pfizer sues J&J over Remicade contracts; drugmakers trim sales forces for rare-disease drugs; Roche's oncology business under siege from biosimilars

Five things for pharma marketers to know: Tuesday, September 19, 2017

Five things for pharma marketers to know: Tuesday, September 19, 2017

By

Only three of the seven FDA-approved biosimilars are available for sale; Teva to sell off women's health portfolio; the FDA approves GSK's COPD combo

Five things for pharma marketers to know: Friday, September 15, 2017

Five things for pharma marketers to know: Friday, September 15, 2017

By

The FDA approves first cancer biosimilar; it also approves Bayer's new lymphoma drug; clinical-trial participation for gynecological cancer drops

Five things for pharma marketers to know: Monday, August 28, 2017

Five things for pharma marketers to know: Monday, August 28, 2017

By

Gilead to acquire Kite; the FDA issues fewest number of warning letters since 2008; the regulator approves BI's Humira biosimilar

Five things for pharma marketers to know: Friday, August 25, 2017

Five things for pharma marketers to know: Friday, August 25, 2017

By

Google surveys for depression; patients with diabetes that adhere to their regimen had fewer ER visits; Biogen, Samsung scores Humira biosimilar approval in EU

Five things for pharma marketers to know: Tuesday, August 15, 2017

Five things for pharma marketers to know: Tuesday, August 15, 2017

By

Pfizer accuses J&J of limiting biosimilar uptake; Trump again criticizes high drug prices; WebMD to reposition site to help consumers manage their health

Five things for pharma marketers to know: Monday, June 12, 2017

Five things for pharma marketers to know: Monday, June 12, 2017

By

Teva gets FDA approval for Truvada generic; the FDA rejects Coherus' Neulasta biosimilar; only 17% of Americans find health industries to be innovative

Five things for pharma marketers to know: Tuesday, May 23, 2017

Five things for pharma marketers to know: Tuesday, May 23, 2017

By

Disease awareness ads can boost drug sales; AstraZeneca's experimental asthma drug cuts steroid use; FDA approves Regeneron and Sanofi's RA drug

Amgen, Sandoz argue biosimilar patent case to the Supreme Court

Amgen, Sandoz argue biosimilar patent case to the Supreme Court

By

Sandoz counsel argued that Amgen's position "wrongly delays the marketing of every biosimilar."

Drugmakers battle for slice of Humira's billions

Drugmakers battle for slice of Humira's billions

By

Makers of biosimilars have targeted a few of the top-selling autoimmune drugs. Get ready for some of the highest-stakes pricing and access skirmishes in recent pharma history.

Five things for pharma marketers to know: Tuesday, March 28, 2017

Five things for pharma marketers to know: Tuesday, March 28, 2017

By

Ovarian cancer drug nabs FDA approval; Senate committee to investigate opioid manufacturers; Allergan's acne drug reports positive Phase-III results

Five things for pharma marketers to know: Friday, March 10, 2017

Five things for pharma marketers to know: Friday, March 10, 2017

By

Novartis' Gleevec shows long-term survival benefit in study; Novo Nordisk CEO considers small acquisitions; Merck KGaA to sell biosimilars unit

Five things for pharma marketers to know: Wednesday, February 15, 2017

Five things for pharma marketers to know: Wednesday, February 15, 2017

By

Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto

Five things for pharma marketers to know: Wednesday, January 18, 2017

Five things for pharma marketers to know: Wednesday, January 18, 2017

By

Rep. Price to answer questions at confirmation hearing; 22 drugmakers invest in fighting disease in poor countries; FDA approves generic of Jazz's Xyrem

 Five things for pharma marketers to know: Friday, January 13, 2017

Five things for pharma marketers to know: Friday, January 13, 2017

By

CVS to sell generic EpiPen; FDA finalizes biosimilar naming rules; Pfizer wants to make a deal

Five things for pharma marketers to know: Tuesday, October 18, 2016

Five things for pharma marketers to know: Tuesday, October 18, 2016

By

Pfizer to start selling Remicade biosimilar in November; The Medicines Co.'s PCSK9 inhibitor heads to Phase-III trials; J&J's Q3 growth bolstered by autoimmune drugs

Five things for pharma marketers to know: Friday, October 14, 2016

Five things for pharma marketers to know: Friday, October 14, 2016

By

Merck launches biosimilar resource; branded insulin prices are on the rise; NICE declines to cover Opdivo

Five things for pharma marketers to know: Monday, October 3, 2016

Five things for pharma marketers to know: Monday, October 3, 2016

By

More drugmakers file lawsuits to prevent biosimilar competition; experimental dermatitis drug showeds promising results; pharma blames PBMs for price hikes

The FDA approves Amgen's biosimilar version of Humira

The FDA approves Amgen's biosimilar version of Humira

By

Amgen's drug is set to compete with AbbVie's Humira, which is the second-best selling drug in the U.S. in 2015.

Five things for pharma marketers to know: Wednesday, August 31, 2016

Five things for pharma marketers to know: Wednesday, August 31, 2016

By

The FDA approves an Enbrel biosimilar; Express Scripts to launch program to reduce diabetes costs; a GSK vaccine beats sales forecasts

Five things for pharma marketers to know: Thursday, August 18, 2016

Five things for pharma marketers to know: Thursday, August 18, 2016

By

Court clears Pfizer to move ahead with Remicade biosimilar; McDonald's yanks activity trackers over skin irritation; California drug-pricing bill pulled

Five things for pharma marketers to know: Friday, July 22, 2016

Five things for pharma marketers to know: Friday, July 22, 2016

By

Herceptin biosimilar meets endpoint in clinical trial; Roche plans to launch five new drugs over the next year; government seeks to block insurer deals

Five things for pharma marketers to know: Thursday, July 14, 2016

Five things for pharma marketers to know: Thursday, July 14, 2016

By

The FDA expands use for Pfizer's Prevnar 13 vaccine; an FDA panel votes in support of Novartis biosimilar; U.S. healthcare spending rises 5.5% in 2015

Merck educates doctors about biosimilars, long before it will sell one in the U.S.

Merck educates doctors about biosimilars, long before it will sell one in the U.S.

By

Drugmakers like Merck are making a big education push as they lay the groundwork for future biosimilars.

What do physicians think about biosimilars?

What do physicians think about biosimilars?

By

A Sermo poll asked physicians: Do you feel biosimilars will prove safe and effective enough for you to prescribe them when more become available?"